FRANCISCO URIBE: Open Payments
NPI 1356751994 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$896 in 52 payments from 7 companies in 2025. Trend: 2023 $312 · 2024 $1,038 · 2025 $896
Food & beverage: $896
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $397 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $155 |
| Vanda Pharmaceuticals Inc. | 6 | $115 |
| Otsuka America Pharmaceutical, Inc. | 5 | $105 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Lundbeck LLC | 2 | $47 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, REXULTI, FANAPT, Auvelity, INGREZZA.
Industry payments across TX — which companies pay providers there.
